GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cotinga Pharmaceuticals Inc (OTCPK:COTQF) » Definitions » Cyclically Adjusted Price-to-FCF

Cotinga Pharmaceuticals (Cotinga Pharmaceuticals) Cyclically Adjusted Price-to-FCF : (As of Jun. 22, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Cotinga Pharmaceuticals Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Cotinga Pharmaceuticals Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Cotinga Pharmaceuticals's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cotinga Pharmaceuticals Cyclically Adjusted Price-to-FCF Chart

Cotinga Pharmaceuticals Annual Data
Trend Apr10 Apr11 Apr12 Apr13 Apr14 Apr15 Apr16 Apr17 Apr18 Apr19
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Cotinga Pharmaceuticals Quarterly Data
Apr15 Jul15 Oct15 Jan16 Apr16 Jul16 Oct16 Jan17 Apr17 Jul17 Oct17 Jan18 Apr18 Jul18 Oct18 Jan19 Apr19 Jul19 Oct19 Jan20
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Cotinga Pharmaceuticals's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Cotinga Pharmaceuticals's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cotinga Pharmaceuticals's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cotinga Pharmaceuticals's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Cotinga Pharmaceuticals's Cyclically Adjusted Price-to-FCF falls into.



Cotinga Pharmaceuticals Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Cotinga Pharmaceuticals's Cyclically Adjusted FCF per Share for the quarter that ended in Jan. 2020 is calculated as:

For example, Cotinga Pharmaceuticals's adjusted Free Cash Flow per Share data for the three months ended in Jan. 2020 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Jan. 2020 (Change)*Current CPI (Jan. 2020)
=-0.003/108.0853*108.0853
=-0.003

Current CPI (Jan. 2020) = 108.0853.

Cotinga Pharmaceuticals Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201004 -0.116 91.651 -0.137
201007 -0.100 92.283 -0.117
201010 -0.072 92.757 -0.084
201101 -0.067 93.074 -0.078
201104 -0.103 94.654 -0.118
201107 -0.091 94.812 -0.104
201110 -0.066 95.444 -0.075
201201 -0.097 95.365 -0.110
201204 -0.082 96.550 -0.092
201207 -0.097 95.997 -0.109
201210 -0.069 96.550 -0.077
201301 -0.069 95.839 -0.078
201304 -0.047 96.945 -0.052
201307 -0.042 97.261 -0.047
201310 -0.050 97.182 -0.056
201401 -0.076 97.261 -0.084
201404 -0.059 98.920 -0.064
201407 -0.084 99.315 -0.091
201410 -0.067 99.473 -0.073
201501 -0.055 98.209 -0.061
201504 -0.056 99.710 -0.061
201507 -0.060 100.579 -0.064
201510 -0.044 100.500 -0.047
201601 -0.066 100.184 -0.071
201604 -0.058 101.370 -0.062
201607 -0.054 101.844 -0.057
201610 -0.058 102.002 -0.061
201701 -0.060 102.318 -0.063
201704 -0.061 103.029 -0.064
201707 -0.058 103.029 -0.061
201710 -0.081 103.424 -0.085
201801 -0.044 104.056 -0.046
201804 -0.022 105.320 -0.023
201807 -0.038 106.110 -0.039
201810 -0.018 105.952 -0.018
201901 0.001 105.557 0.001
201904 -0.003 107.453 -0.003
201907 -0.008 108.243 -0.008
201910 -0.004 107.927 -0.004
202001 -0.003 108.085 -0.003

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Cotinga Pharmaceuticals  (OTCPK:COTQF) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Cotinga Pharmaceuticals Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Cotinga Pharmaceuticals's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Cotinga Pharmaceuticals (Cotinga Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
82 Richmond Street East, The Canadian Venture Building, Toronto, ON, CAN, M5C1P1
Cotinga Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's lead clinical candidate, COTI-2, is an oral small molecule targeting p53, a tumor suppressor gene that is mutated in over 50% of all cancers, and the company's second clinical candidate, COTI-219, is a novel oral small molecule compound targeting the mutant forms of KRAS with such mutations occurring in up to 30% of all cancers.

Cotinga Pharmaceuticals (Cotinga Pharmaceuticals) Headlines

From GuruFocus

Cotinga Pharmacueticals Announces Closing of Unit Offering

By GlobeNewswire GlobeNewswire 05-22-2019